Brookline Capital Markets Reiterates Moderna (MRNA) at Buy, Believes New Vaccine Candidates Present Potential Upside to Long-Term Outlook
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $506.00 price target on Moderna (NASDAQ: MRNA), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
